


**Alexa Fluor® 647 anti-human CD304 (Neuropilin-1)**


<b>Catalog # / Size:</b>	2372585 / 25 tests 2372590 / 100 tests
<b>Clone:</b>	12C2
<b>Isotype:</b>	Mouse IgG2a, κ
<b>Immunogen:</b>	CD304-Fc Fusion protein
<b>Reactivity:</b>	Human
<b>Preparation:</b>	The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 647 under optimal conditions.
<b>Formulation:</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).
<b>Concentration:</b>	Lot-specific



Human peripheral blood mononuclear cells were stained with CD303 PE and CD304 (clone 12C2) Alexa Fluor® 647 (top) or mouse IgG2a, κ Alexa Fluor® 647 isotype control (bottom). Data shown was gated on lymphocyte and monocyte populations.

**Applications:**

<b>Applications:</b>	Flow Cytometry
<b>Recommended Usage:</b>	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



\* Alexa Fluor® 647 has a maximum emission of 668 nm when it is excited at 633 nm / 635 nm.

**Description:** CD304, also known as neuropilin-1, BDCA-4 and VEGF165R, is a 140 kD type I transmembrane protein. Its extracellular region contains 2 CUB, 2 FV/FVIII, and one MAM domain; a soluble isoform is produced by alternative mRNA splicing. CD304 is involved in angiogenesis, neural development, and tumor metastasis. It's expressed by plasmacytoid dendritic cells, thymocytes, neurons, endothelium, and a subset of T<sub>FH</sub> cells. CD304 is also expressed in several carcinomas, and a high expression of this molecule in prostate cancer correlates with a poor prognosis.

<b>Antigen</b>	1. Mizui M and Kikutani H. 2008. <i>Immunity</i> 28:302.
<b>References:</b>	2. Hamerlik P, <i>et al.</i> 2012. <i>J. Exp. Med.</i> 209:507.
	3. Karjalainen K, <i>et al.</i> 2011. <i>Blood</i> 117:920.

4. Lepelletier Y, *et al.* 2007.